Phase 3: upcoming dates

Health09/20/2026@HealthDesk

REGN7508's Phase 3 Trial in Venous Thromboembolism Reads Out

Regeneron PharmaceuticalsEastview, Mount Pleasant, United States

Starts 02/20/2027ESTIMATED50% CONFIDENCEin 139 daysClinicalTrials.gov^[1] lists 2027-02-20 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

Regeneron Pharmaceuticals's phase 3 trial of REGN7508 in venous thromboembolism reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,000 participants. This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery. The aim of the study is to see how effective the study drug is at preventing Venous Thromboembolism (VTE) and other related diseases after total knee replacement surgery. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Health09/20/2026@HealthDesk

REGN7508's Phase 3 Trial in Venous Thromboembolism Reads Out

Regeneron PharmaceuticalsEastview, Mount Pleasant, United States

Starts 02/20/2027ESTIMATED50% CONFIDENCEin 139 daysClinicalTrials.gov^[1] lists 2027-02-20 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

Health09/20/2026@HealthDesk

Camizestrant's Phase 3 Trial in Breast Cancer, Early Breast Cancer Reads Out

AstraZenecaCambridge, United Kingdom

Starts 04/20/2027ESTIMATED50% CONFIDENCEin 198 daysClinicalTrials.gov^[1] lists 2027-04-20 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

AstraZeneca's phase 3 trial of Camizestrant in breast cancer, early breast cancer reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,300 participants. This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.

Health09/20/2026@HealthDesk

REGN7508's Phase 3 Trial in Symptomatic Venous Thromboembolism Reads Out

Regeneron PharmaceuticalsEastview, Mount Pleasant, United States

Starts 05/17/2027ESTIMATED50% CONFIDENCEin 225 daysClinicalTrials.gov^[1] lists 2027-05-17 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

Regeneron Pharmaceuticals's phase 3 trial of REGN7508 in symptomatic venous thromboembolism reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,000 participants. This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called Acetylsalicylic Acid (ASA). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery. The aim of the study is to see how effective the study drug is at preventing Venous Thromboembolism (VTE) and other related diseases after total knee replacement surgery compared to acetylsalicylic acid. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)

Health09/20/2026@HealthDesk

PCV21 Vaccine's Phase 3 Trial in Pneumococcal Immunization Reads Out

SanofiParis, Grand Paris, France

Starts 06/07/2027ESTIMATED50% CONFIDENCEin 246 daysClinicalTrials.gov^[1] lists 2027-06-07 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

Sanofi's phase 3 trial of PCV21 Vaccine in pneumococcal immunization reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,195 participants. This is a phase 3 randomized, modified double-blind study whose purpose is to measure whether 3 lots of the investigational pneumococcal vaccine PCV21 can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) in a similar way (ie, same immune response) when they are given to infants aged from approximately 2 months (42 to 89 days) and are safe compared to a licensed 20-valent pneumococcal vaccine (20vPCV) (Prevnar 20™). The study duration per participant will be up to approximately 17 months. The study vaccines (either PCV21 or 20vPCV) will be administered at approximately 2, 4, 6 and 12 months of age.

Health09/20/2026@HealthDesk

Armour Thyroid's Phase 3 Trial in Hypothyroidism Reads Out

AbbVieNorth Chicago, United States

Starts 09/01/2027ESTIMATED50% CONFIDENCEin 332 daysClinicalTrials.gov^[1] gives the primary completion date only as 2027-09, an estimate by the sponsor, so the pin sits on the first of that month.

AbbVie's phase 3 trial of Armour Thyroid in hypothyroidism reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,800 participants. This study will evaluate the efficacy and safety of Armour Thyroid treatment compared with synthetic T4 in subjects who have primary hypothyroidism and are currently stabilized (i.e., in-range thyroid-stimulating hormone \[TSH\]) on synthetic T4 treatment. This study will also therefore evaluate the efficacy and safety of dose conversion from synthetic T4 therapy to Armour Thyroid therapy.

Health09/20/2026@HealthDesk

Ibuzatrelvir's Phase 3 Trial in COVID-19 SARS-CoV-2 Infection Reads Out

PfizerNew York City, New York, United States

Starts 10/03/2027ESTIMATED50% CONFIDENCEin 364 daysClinicalTrials.gov^[1] lists 2027-10-03 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

Pfizer's phase 3 trial of Ibuzatrelvir in covid-19 sars-cov-2 infection reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,330 participants. The purpose of the study is to evaluate whether ibuzatrelvir is effective and safe in adults and adolescents with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible participants will be randomly assigned (by chance) to receive ibuzatrelvir or matching placebo orally for 5 days. Co-administration of locally available standard of care is allowed. The total duration of the study is around 6 months.

Health09/20/2026@HealthDesk

MK-8527's Phase 3 Trial in Human Immunodeficiency Virus Reads Out

Merck & Co.Rahway, United States

Starts 10/18/2027ESTIMATED50% CONFIDENCEin 1.0 yearsClinicalTrials.gov^[1] lists 2027-10-18 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

Merck & Co.'s phase 3 trial of MK-8527 in human immunodeficiency virus reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,580 participants. Researchers are looking for new medicines to prevent HIV-1 (Human Immunodeficiency Virus Type 1) infection.

Health09/20/2026@HealthDesk

Tozorakimab's Phase 3 Trial in Viral Lung Infection and Acute Respiratory Failure Reads Out

AstraZenecaCambridge, United Kingdom

Starts 11/04/2027ESTIMATED50% CONFIDENCEin 1.1 yearsClinicalTrials.gov^[1] lists 2027-11-04 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

AstraZeneca's phase 3 trial of Tozorakimab in viral lung infection and acute respiratory failure reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 3,527 participants. The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.

Health09/20/2026@HealthDesk

BGF MDI 320/14.4/9.6 μG's Phase 3 Trial in COPD Reads Out

AstraZenecaCambridge, United Kingdom

Starts 12/03/2027ESTIMATED50% CONFIDENCEin 1.2 yearsClinicalTrials.gov^[1] lists 2027-12-03 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

AstraZeneca's phase 3 trial of BGF MDI 320/14.4/9.6 μG in copd reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 5,000 participants. This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.

Health09/20/2026@HealthDesk

Maridebart Cafraglutide's Phase 3 Trial in Obesity Reads Out

AmgenThousand Oaks, United States

Starts 12/26/2027ESTIMATED50% CONFIDENCEin 1.2 yearsClinicalTrials.gov^[1] lists 2027-12-26 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

Amgen's phase 3 trial of Maridebart Cafraglutide in obesity reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 3,200 participants. The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839).

Health09/20/2026@HealthDesk

Cagrisema's Phase 3 Trial in Obesity Reads Out

Novo NordiskBagsværd, Gladsaxe Municipality, Denmark

Starts 02/23/2028ESTIMATED50% CONFIDENCEin 1.4 yearsClinicalTrials.gov^[1] lists 2028-02-23 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

Novo Nordisk's phase 3 trial of Cagrisema in obesity reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,500 participants. This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive either CagriSema or semaglutide, and which treatment participants receive is decided by chance. CagriSema is a new study medicine being tested, while semaglutide is a medicine that doctors can already prescribe.

Health09/20/2026@HealthDesk

MenQuadfi's Phase 3 Trial in Meningococcal Infection Reads Out

SanofiParis, Grand Paris, France

Starts 03/13/2028ESTIMATED50% CONFIDENCEin 1.4 yearsClinicalTrials.gov^[1] lists 2028-03-13 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

Sanofi's phase 3 trial of MenQuadfi in meningococcal infection reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,568 participants. The purpose of this study is to describe the safety and immunogenicity of MenACYW conjugate vaccine compared with locally-licensed meningococcal vaccines in healthy infants and toddlers in China. Study details include: * Study duration (including 6-month safety follow-up after the last dose): * Cohort I (Groups 1 and 2): approximately 211 or 271 days (approximately 7 or 9 months) * Cohort II (Groups 3 and 4): up to 18 months * Cohort III (Groups 5 and 6): up to 21 months * Cohort III (Group 7): approximately 16 months * Vaccination Visits Period: * Cohort I (Groups 1 and 2): a 2-dose vaccination at V01 (D01) and V02 (D31) or V03 (D91). Two blood samples are collected pre-vaccination (D01) and 30 days post the 2nd dose of vaccination (D61 or D121).

Health09/20/2026@HealthDesk

Vicadrostat's Phase 3 Trial in Heart Failure Reads Out

Boehringer IngelheimIngelheim am Rhein, Mainz-Bingen district, Germany

Starts 05/22/2028ESTIMATED50% CONFIDENCEin 1.6 yearsClinicalTrials.gov^[1] lists 2028-05-22 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

Boehringer Ingelheim's phase 3 trial of Vicadrostat in heart failure reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 6,000 participants. This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Participants are put into 2 groups by chance. Every participant has an equal chance of being in each group. The groups are: * Vicadrostat/empagliflozin group: participants take vicadrostat/empagliflozin as tablets once a day. * Placebo/empagliflozin group: participants take placebo/empagliflozin as tablets once a day. Participants can stay in the study as long as they benefit from treatment and can tolerate it. During this time, they visit their doctors regularly. The doctors regularly check participants' health and take note of any unwanted effects.

Health09/20/2026@HealthDesk

MRNA Seasonal Flu Vaccine's Phase 3 Trial in Influenza, Human Reads Out

GSK79 New Oxford Street, London, Greater London, United Kingdom

Starts 06/09/2028ESTIMATED50% CONFIDENCEin 1.7 yearsClinicalTrials.gov^[1] lists 2028-06-09 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

GSK's phase 3 trial of MRNA Seasonal Flu Vaccine in influenza, human reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 54,000 participants. This study will compare an investigational mRNA flu vaccine with a licensed flu vaccine in adults 65 years of age and older. Participants will receive one injection and will be followed during the flu season. The study will measure prevention of laboratory-confirmed flu illness, side effects, and immune responses.

Health09/20/2026@HealthDesk

Maridebart Cafraglutide's Phase 3 Trial in Atherosclerotic Cardiovascular Disease Reads Out

AmgenThousand Oaks, United States

Starts 06/30/2028ESTIMATED50% CONFIDENCEin 1.7 yearsClinicalTrials.gov^[1] lists 2028-06-30 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

Amgen's phase 3 trial of Maridebart Cafraglutide in atherosclerotic cardiovascular disease reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 12,800 participants. The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

Health09/20/2026@HealthDesk

Maridebart Cafraglutide's Phase 3 Trial in Heart Failure With Preserved Ejection Fraction Reads Out

AmgenThousand Oaks, United States

Starts 06/30/2028ESTIMATED50% CONFIDENCEin 1.7 yearsClinicalTrials.gov^[1] lists 2028-06-30 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

Amgen's phase 3 trial of Maridebart Cafraglutide in heart failure with preserved ejection fraction reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 5,056 participants. This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE). The trial is event-driven, and Part 1 will conclude when approximately 850 primary endpoint events have occurred.

Health09/20/2026@HealthDesk

Elecoglipron's Phase 3 Trial in Type 2 Diabetes Mellitus Reads Out

AstraZenecaCambridge, United Kingdom

Starts 07/05/2028ESTIMATED50% CONFIDENCEin 1.8 yearsClinicalTrials.gov^[1] lists 2028-07-05 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

AstraZeneca's phase 3 trial of Elecoglipron in type 2 diabetes mellitus reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,000 participants. The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.

Health09/20/2026@HealthDesk

Enicepatide's Phase 3 Trial in Obesity or Overweight Reads Out

RocheBasel, Canton of Basel-Stadt, Switzerland

Starts 07/24/2028ESTIMATED50% CONFIDENCEin 1.8 yearsClinicalTrials.gov^[1] lists 2028-07-24 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

Roche's phase 3 trial of Enicepatide in obesity or overweight reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,000 participants. The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity.

Health09/20/2026@HealthDesk

Elecoglipron's Phase 3 Trial in Weight Management Reads Out

AstraZenecaCambridge, United Kingdom

Starts 07/31/2028ESTIMATED50% CONFIDENCEin 1.8 yearsClinicalTrials.gov^[1] lists 2028-07-31 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

AstraZeneca's phase 3 trial of Elecoglipron in weight management reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,500 participants. This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adults living with obesity or overweight with at least one weight-related comorbidity, and without T2DM (Study 1) or with T2DM (Study 2).

Health09/20/2026@HealthDesk

AZD6234's Phase 3 Trial in Obesity or Overweight Reads Out

AstraZenecaCambridge, United Kingdom

Starts 08/11/2028ESTIMATED50% CONFIDENCEin 1.9 yearsClinicalTrials.gov^[1] lists 2028-08-11 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

AstraZeneca's phase 3 trial of AZD6234 in obesity or overweight reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,500 participants. The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity.

Health09/20/2026@HealthDesk

BI 690517's Phase 3 Trial in Kidney Disease, Chronic Reads Out

Boehringer IngelheimIngelheim am Rhein, Mainz-Bingen district, Germany

Starts 08/30/2028ESTIMATED50% CONFIDENCEin 1.9 yearsClinicalTrials.gov^[1] lists 2028-08-30 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

Boehringer Ingelheim's phase 3 trial of BI 690517 in kidney disease, chronic reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 11,000 participants. This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study. The study is open to people who take other medicines called angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). People who already take empagliflozin or any other sodium-glucose cotransporter-2 inhibitor (SGLT2i) can also join. The study is also open to people who currently do not take any of these treatments. The purpose of this study is to find out whether a medicine called BI 690517 helps people with chronic kidney disease when taken in combination with a study medicine called empagliflozin. Worsening of kidney function increases the risk for kidney failure, cardiovascular disease, and heart failure hospitalisation.

Health09/20/2026@HealthDesk

C.Difficile Vaccine's Phase 3 Trial in Clostridoides Difficile Associated Disease Reads Out

PfizerNew York City, New York, United States

Starts 12/11/2028ESTIMATED50% CONFIDENCEin 2.2 yearsClinicalTrials.gov^[1] lists 2028-12-11 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

Pfizer's phase 3 trial of C.Difficile Vaccine in clostridoides difficile associated disease reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 32,500 participants. The purpose of the study is to learn about how effective, safe, and tolerable the Clostridioides difficile (C. difficile) vaccine is in decreasing the number of C. difficile infections (pCDI) in adults 65 years of age or older. The participants will receive either the C. difficile vaccine or placebo (saline). A placebo does not contain any active ingredients. The vaccines will be given as a shot into the upper arm muscle. This study looks at the number of diarrhea (loose stools) events related to a C. difficile infection, so the length of the study can change. If these events happen quickly, the study may finish sooner; if they happen slowly, it could take longer. Sometimes, the study might stop early if the vaccine clearly does not work. Participants will stay in the study until enough events have occurred to answer the main question.

Health09/20/2026@HealthDesk

PG4's Phase 3 Trial in Pneumococcal Disease Reads Out

PfizerNew York City, New York, United States

Starts 12/30/2028ESTIMATED50% CONFIDENCEin 2.2 yearsClinicalTrials.gov^[1] lists 2028-12-30 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.

Pfizer's phase 3 trial of PG4 in pneumococcal disease reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,400 participants. The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs that can cause pneumonia (lung infections), meningitis (brain infections), and otitis media (ear infections) in infants when compared to the pneumococcal vaccine that is currently in use, 20vPnC (Prevnar 20®). This study will test if the new pneumococcal vaccine is as safe as the one that is currently in use. This new vaccine can possibly provide additional protection against germs that cause pneumococcal disease that are not included in the vaccines that are currently given to infants. Pneumococcal disease includes a variety of infections caused by a specific germ, Streptococcus pneumoniae. There are two groups in this study. All participants will be assigned to one of the two groups.

Health09/23/2026@HealthDesk

Caplyta Hits Its Goal in a Phase 3 Bipolar Mania Trial

Titusville, Hopewell Township, Mercer County, New Jersey, United States

Johnson & Johnson

Caplyta Hits Its Goal in a Phase 3 Bipolar Mania Trial

Starts 09/21/2026 12:00PM UTCCONFIRMED85% CONFIDENCE13 days agoThe release is datelined "TITUSVILLE, N.J. (September 21, 2026) - Johnson & Johnson (NYSE: JNJ^[1][4]) today announced positive topline results from the pivotal Phase 3 study", and its PR Newswire copy is timestamped "Sep 21, 2026, 08:00 ET" (12:00 UTC).

Johnson & Johnson reported positive topline results from Study 451: once-daily Caplyta (lumateperone) 42 mg cut manic symptoms in bipolar I disorder by 4.8 YMRS points more than placebo at week 3, with a significant effect from day 3.

Health09/23/2026@HealthDesk

Retatrutide Delivers 28.3% Weight Loss in Lilly's TRIUMPH-1 Phase 3 Trial

Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States

Eli Lilly

Retatrutide Delivers 28.3% Weight Loss in Lilly's TRIUMPH-1 Phase 3 Trial

Starts 05/21/2026CONFIRMED87% CONFIDENCE136 days agoLilly's release is datelined "INDIANAPOLIS, May 21, 2026" and says the company "today announced positive topline results from TRIUMPH-1".^[1]

People on the top 12 mg dose of Lilly's triple-hormone shot retatrutide lost an average of 28.3% of their body weight (70.3 lbs) over 80 weeks, and 30.3% by two years in the extension - weight loss at the level of bariatric surgery.

Phase 3: upcoming dates

Upcoming

REGN7508's Phase 3 Trial in Venous Thromboembolism Reads Out

Related tags

Companies

Phase 3: upcoming dates

Upcoming

REGN7508's Phase 3 Trial in Venous Thromboembolism Reads Out

Related tags

Companies

Camizestrant's Phase 3 Trial in Breast Cancer, Early Breast Cancer Reads Out

REGN7508's Phase 3 Trial in Symptomatic Venous Thromboembolism Reads Out

PCV21 Vaccine's Phase 3 Trial in Pneumococcal Immunization Reads Out

Armour Thyroid's Phase 3 Trial in Hypothyroidism Reads Out

Ibuzatrelvir's Phase 3 Trial in COVID-19 SARS-CoV-2 Infection Reads Out

MK-8527's Phase 3 Trial in Human Immunodeficiency Virus Reads Out

Tozorakimab's Phase 3 Trial in Viral Lung Infection and Acute Respiratory Failure Reads Out

BGF MDI 320/14.4/9.6 μG's Phase 3 Trial in COPD Reads Out

Maridebart Cafraglutide's Phase 3 Trial in Obesity Reads Out

Cagrisema's Phase 3 Trial in Obesity Reads Out

MenQuadfi's Phase 3 Trial in Meningococcal Infection Reads Out

Vicadrostat's Phase 3 Trial in Heart Failure Reads Out

MRNA Seasonal Flu Vaccine's Phase 3 Trial in Influenza, Human Reads Out

Maridebart Cafraglutide's Phase 3 Trial in Atherosclerotic Cardiovascular Disease Reads Out

Maridebart Cafraglutide's Phase 3 Trial in Heart Failure With Preserved Ejection Fraction Reads Out

Elecoglipron's Phase 3 Trial in Type 2 Diabetes Mellitus Reads Out

Enicepatide's Phase 3 Trial in Obesity or Overweight Reads Out

Elecoglipron's Phase 3 Trial in Weight Management Reads Out

AZD6234's Phase 3 Trial in Obesity or Overweight Reads Out

BI 690517's Phase 3 Trial in Kidney Disease, Chronic Reads Out

C.Difficile Vaccine's Phase 3 Trial in Clostridoides Difficile Associated Disease Reads Out

PG4's Phase 3 Trial in Pneumococcal Disease Reads Out

Recent

Caplyta Hits Its Goal in a Phase 3 Bipolar Mania Trial

Retatrutide Delivers 28.3% Weight Loss in Lilly's TRIUMPH-1 Phase 3 Trial